Literature DB >> 30132526

MicroRNA-1254 exerts oncogenic effects by directly targeting RASSF9 in human breast cancer.

Bin Li1, Peng Chen2, Jialin Wang3, Linxia Wang4, Mingzhi Ren5, Ruisan Zhang2, Jianjun He6.   

Abstract

MicroRNAs (miRNAs or miRs) play crucial roles in human breast cancer. Although miR-1254 has been shown to have oncogenic activity in several cancer types, its biological function in breast cancer and its mechanisms of action remain unclear. In this study, we investigated the role of miR-1254 in human breast cancer and sought to elucidate the relevant underlying mechanisms. We found that miR-1254 expression was markedly increased in breast cancer tissues and cell lines. Additionally, miR-1254 overexpression accelerated breast cancer cell proliferation, cell cycle G1-S phase transition and inhibited apoptosis. Nevertheless, the inhibition of miR-1254 suppressed cell proliferation and induced apoptosis. Further analyses revealed that miR-1254 expression negatively correlated with RASSF9 expression in breast cancer tissues. We verified that RASSF9 was a direct target of miR-1254 using a luciferase reporter assay. The overexpression of miR-1254 reduced the RASSF9 mRNA and protein levels, and the suppression of miR-1254 promoted RASSF9 expression. Notably, the knockdown or overexpression of RASSF9 corroborated the biological effects observed upon miR-1254 overexpression or inhibition. Taken together, these results demonstrate that miR-1254 accelerates breast cancer cell growth by activating the AKT signaling pathway and suppresses apoptosis by inhibiting p53 expression through the targeting of RASSF9. The data indicate that miR-1254 plays a crucial role in human breast cancer, and may represent a novel therapeutic target for this malignancy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30132526     DOI: 10.3892/ijo.2018.4530

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  MiR-1254 and MEGF6 regulates oxaliplatin resistance in human colorectal cancer cells.

Authors:  Yueyang Mou; Nabin He; Mengyang Su; Zihua Zhong; Jiayu Ma; Jianling Liu; Xi'an Cheng; Penggao Dai
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  Expression significance and potential mechanism of hypoxia-inducible factor 1 alpha in patients with myelodysplastic syndromes.

Authors:  Hai-Wei Liang; Bin Luo; Li-Hua Du; Rong-Quan He; Gang Chen; Zhi-Gang Peng; Jie Ma
Journal:  Cancer Med       Date:  2019-08-14       Impact factor: 4.452

3.  MiR-1254 Functions as a Tumor Suppressor in Oral Squamous Cell Carcinoma by Targeting CD36.

Authors:  Ruixue Chen; Yang Zhang; Xudong Zhang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

Review 4.  MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.

Authors:  Mohammad Mijanur Rahman; Andrew C Brane; Trygve O Tollefsbol
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

5.  MicroRNA-1269 promotes cell proliferation via the AKT signaling pathway by targeting RASSF9 in human gastric cancer.

Authors:  Wen-Li Liu; Hu-Xia Wang; Cheng-Xin Shi; Fei-Yu Shi; Ling-Yu Zhao; Wei Zhao; Guang-Hui Wang
Journal:  Cancer Cell Int       Date:  2019-11-21       Impact factor: 5.722

6.  Upregulation of miR-1254 promotes Hepatocellular Carcinoma Cell Proliferation, Migration, and Invasion via Inactivation of the Hippo-YAP signaling pathway by decreasing PAX5.

Authors:  Xu Lu; Chao Yang; Yuanchang Hu; Jian Xu; Chengyu Shi; Jianhua Rao; Weixin Yu; Feng Cheng
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

7.  miR-1254 induced by NESG1 inactivates HDGF/DDX5-stimulated nuclear translocation of β-catenin and suppresses NPC metastasis.

Authors:  Chao Cheng; Wenmin Li; Xuemei Peng; Xiong Liu; Ziyan Zhang; Zhen Liu; Tongyuan Deng; Rongcheng Luo; Weiyi Fang; Xiaojie Deng
Journal:  Mol Ther Methods Clin Dev       Date:  2021-02-04       Impact factor: 6.698

8.  MR1 overexpression correlates with poor clinical prognosis in glioma patients.

Authors:  Phillip Kubica; Montserrat Lara-Velazquez; Marpe Bam; Seema Siraj; Irene Ong; Peng Liu; Raj Priya; Shahriar Salamat; Randy R Brutkiewicz; Mahua Dey
Journal:  Neurooncol Adv       Date:  2021-02-20

9.  TAK1 Phosphorylates RASSF9 and Inhibits Esophageal Squamous Tumor Cell Proliferation by Targeting the RAS/MEK/ERK Axis.

Authors:  Hui Shi; Qianqian Ju; Yinting Mao; Yuejun Wang; Jie Ding; Xiaoyu Liu; Xin Tang; Cheng Sun
Journal:  Adv Sci (Weinh)       Date:  2021-01-06       Impact factor: 16.806

10.  RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis.

Authors:  Jun Yuan; Qianqian Ju; Jun Zhu; Yun Jiang; Xuechao Yang; Xiaoyu Liu; Jinyu Ma; Cheng Sun; Jiahai Shi
Journal:  Cell Death Discov       Date:  2021-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.